View printer-friendly version

Download PDF

New Studies Conclude BioThrax Plus Antibiotics Provide 100% Protection In Animals When Administered After Anthrax Exposure

Findings add support for Emergency Use Authorization of BioThrax for post-exposure prophylaxis

GAITHERSBURG, MD, January 10, 2006— Two separate government-sponsored studies demonstrated that BioThrax (Anthrax Vaccine Adsorbed), the world’s only FDA-licensed anthrax vaccine produced by Emergent BioSolutions Inc., provided 100% protection against death in anthrax-infected animals treated with BioThrax combined with antibiotics. This was a significant improvement over antibiotic treatment alone.

“These studies demonstrated that post-exposure vaccination enhanced the protection afforded by antibiotic prophylaxis alone,” said Fuad El-Hibri, Chairman and Chief Executive Officer of Emergent BioSolutions Inc. “The addition of BioThrax to antibiotic therapy protected animals against inhalational anthrax and provided evidence that post-exposure vaccination can shorten the duration of antibiotic prophylaxis required. This approach has the ability to significantly improve public health management following a bioterrorism event.”

In a study sponsored by NIAID (National Institute of Allergy and Infectious Disease) and performed at USAMRIID (United States Army Medical Research Institute of Infectious Disease), it was shown that in non-human primates infected by aerosol exposure with 1600 times the lethal dose of spores treated with a 14-day course of antibiotics alone, significant mortality was seen after antibiotics were discontinued. Antibiotic therapy in combination with post-infection BioThrax vaccination using the licensed schedule provided protection against death in 100% of the animals tested (10 of 10). These study results were presented in October at the 43rd Annual Meeting of the Infectious Disease Society of America.

Preliminary results from a similar study performed in rabbits, sponsored by NIAID (National Institute of Allergy and Infectious Disease) and performed at Battelle Memorial Institute, indicate the animals were protected against death when treated with BioThrax plus antibiotics after aerosol exposure to anthrax spores, under conditions where antibiotic prophylaxis alone was only partially protective.

“These studies provide the strongest evidence to date that a combination of BioThrax and antibiotics is an effective way to treat inhalation anthrax in a post-exposure setting and strengthens support for Emergency Use Authorization of BioThrax in the event of another anthrax attack,” said El-Hibri. “Results from the referenced studies provide additional support to our ongoing program to add a post-exposure indication to the already licensed pre-exposure indication.”

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is dedicated to the research, development, and manufacture of novel products which harness the immune system to prevent and treat disease. These include products for prophylactic and therapeutic use against common infectious diseases and against biological weapons. The company currently employs more than 400 people with facilities in Gaithersburg and Frederick, Maryland, Lansing, Michigan, Berkshire, UK, and Munich, Germany. More information about Emergent BioSolutions and its subsidiaries can be found at www.ebsi.com.